The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Brianne Weingarten - One of the best experts on this subject based on the ideXlab platform.
-
an iterative model for in vitro Laboratory Assessment of tamper deterrent formulations
Drug and Alcohol Dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:Abstract Background In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Methods Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. Results A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to “real-world” scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. Conclusions This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties.
-
An iterative model for in vitro Laboratory Assessment of tamper deterrent formulations.
Drug and alcohol dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to "real-world" scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Edward J Cone - One of the best experts on this subject based on the ideXlab platform.
-
an iterative model for in vitro Laboratory Assessment of tamper deterrent formulations
Drug and Alcohol Dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:Abstract Background In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Methods Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. Results A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to “real-world” scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. Conclusions This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties.
-
An iterative model for in vitro Laboratory Assessment of tamper deterrent formulations.
Drug and alcohol dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to "real-world" scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Jennifer Giordano - One of the best experts on this subject based on the ideXlab platform.
-
an iterative model for in vitro Laboratory Assessment of tamper deterrent formulations
Drug and Alcohol Dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:Abstract Background In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Methods Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. Results A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to “real-world” scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. Conclusions This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties.
-
An iterative model for in vitro Laboratory Assessment of tamper deterrent formulations.
Drug and alcohol dependence, 2013Co-Authors: Edward J Cone, Jennifer Giordano, Brianne WeingartenAbstract:In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for Laboratory Assessment of tamper deterrent properties of new formulations have not previously been developed. Experimental designs were developed for the in vitro Laboratory Assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable Laboratory testing. A description of the model is provided along with pertinent examples involving Assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to "real-world" scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration. This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the Assessment of other drug formulations designed to exhibit tamper deterrence properties. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Diana A. Gorog - One of the best experts on this subject based on the ideXlab platform.
-
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
International journal of molecular sciences, 2021Co-Authors: Vassilios P. Memtsas, Deepa R. J. Arachchillage, Diana A. GorogAbstract:Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and Laboratory Assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in various disease states and Assessment of cardiovascular risk.
F D Morrow - One of the best experts on this subject based on the ideXlab platform.
-
Laboratory measurements of nutritional status as correlates of atrophic glossitis
Journal of General Internal Medicine, 1991Co-Authors: Paul J. Drinka, Elizabeth Langer, Linda Scott, F D MorrowAbstract:Objective:To perform a comprehensive Laboratory Assessment of nutritional status in two elderly patients selected for the presence of atrophic glossitis, a classic physical sign of malnutrition.
